Rosa Peracaula Miró
Associate Professor and co-director of the research group Biochemistry of Cancer (GRCT003) at the University of Girona
Biochemistry and Molecular Biology Unit. Biology Department, Faculty of Sciences. University of Girona. 17071 Girona, Spain.
Phone: +00 (34) 972 418 370
E-mail: rosa.peracaula@udg.edu
ORCID: 0000-0003-3513-524X
Member of SEBBM (Sociedad Española de Bioquímica y Biología Molecular) and ASEICA (Asociación Española de Investigación contra el Cáncer)
Brief CV:
Doctor in Chemical Sciences from the Ramon Llull University (1995). Since 1995 I joined the Biochemistry group of the University of Girona (UdG), combining teaching, and research activity in glycoproteins, under the supervision of Dr. R. de Llorens. In this area, I performed postdoctoral stays at the MD Anderson Cancer Center in Houston (1997), in the laboratory of Dr. M. Frazier, specialist in gastrointestinal cancers, and later at the University of Oxford (2001 and 2002) in the laboratory of Dr. R. Dwek and Dr. P. Rudd (currently at NIBRT, Dublin), where I specialized in Glycobiology.
Since 2003, I am professor of Biochemistry and Molecular Biology at the UdG, where I co-direct the research group "Biochemistry of Cancer" and I am also the coordinator of the research group SGR Clinic and Biochemistry of Cancer (ref 2021 SGR 00562) recognized by the Generalitat de Catalunya, which integrates the basic researchers of our group at the UdG and clinicians of the Hospital Dr. Josep Trueta.
Since I got my position at UdG, I have increased my docent task, lecturing a higher number of theoretical subjects as well as lecturing in master and doctorate courses. I have also had several academic management positions; to highlight as a academic secretary of the Biology Dept. from July-2004 to Nov.-2007, and as a coordinator of the Biology degree from Sept.-2009 to Dec-2012.
My research focuses on the area of glycobiology and cancer, where, from 2004 to the present, I have participated as a researcher or responsible researcher in 33 projects, have led as principal investigator (IP) in six competitive R&D projects (five financed by the Ministry of Science and Innovation and one by the La Marató Foundation of TV3; all three years long), in relation to the search for new tumor markers associated with altered glycosylation of proteins and in relation to the role of sialyltransferases in the invasion and metastasis of tumor cells.
The scientific experience of the research group has generated seven R&D contracts with Companies (national and international), in which I have participated as a researcher (in three of them) and in the other four, I have been the principal investigator (IP).
All this has allowed the generation of five patents and more than 49 scientific articles in international journals, some with more than 200 citations, and four book chapters. Of the 49 articles published, 41 from the first quartile (JCR or SJR) and 34 articles as first or last/corresponding author, with an H index=29.
I have directed ten Doctoral Theses, seven of them with European Mention, and three Doctoral Theses more in progress; and numerous works of DEA, Master and TFG. I have also participated in dissemination of the research to society through participation in conferences aimed at the general public and in scientific campaigns addressed to secondary school students.
I have also lectured at national and international symposia, and our group is part of the European network of the EuroGlycoscience Forum and the INNOGLY- COST Action, and member of ALIPANC organization.
My research activity has been recognised in four research sexennial periods (1992-2000, 2001-07, 2008-13 and 2014-19) and one sexennial period of knowledge transfer and innovation (2010-2018), and since October 1, 2019, I am accredited as Full Professor by ANECA.
Our research group actively collaborates with different national and international groups of recognized prestige. To highlight the group of Drs. R. Saldova/P Rudd from the NIBRT (Dublin), experts in glycobiology, who have been participating in our funded projects, the group of Dr. K. Konstantopoulos of Johns Hopkins University of Baltimore, expert in the processes of adhesion and tumor cell migration. The study of altered glycosylation in prostate cancer has also led to collaborations with Dr. P. Mendes of the University of Birmingham, participating in a project of the UK Prostate Cancer Foundation, and with Dr. J. Munkley of the University of Newcastle. At the national level, to highlight the collaborations with Dr. P. Navarro from IMIM (Barcelona), with Drs. E. Giménez and MV. Sanz-Nebot from the Univ. of Barcelona, with Dr. O. Pozo, from IMIM, and Dr. PE.Guerrero/JM Garcia-Aznar from Univ. of Zaragoza, among others. Recently, collaborations with Dr. A. González group from the Univ. of Vigo and with Dr. A Palazón from the CICbioGUNE (Spain) have been established.
The investigations performed over these years have a marked translational component, and therefore we collaborate closely with the clinicians of the Dr. J. Trueta Hospital in Girona, who have been participating in the different research projects in the definition of clinical problem and patient selection. All this has allowed us to advance in the knowledge of glycan alterations associated with tumors and has opened new strategies to find biomarkers to improve the diagnosis and prognosis of pancreatic and prostate cancer.
Projects (last 10 years):
- “Altered glycosylation in pancreatic cancer: Basis to develop novel biomarkers and therapeutic targets (GLYCOPAC)”. MICINN. PID2020-115686RB-I00. 09/2021- 09/2024. IP: Drs. Rosa Peracaula/Esther Llop.
- Non-invasive biomarkers for Prostate Cancer clinical risk stratification: PSA glycoforms and multiparametric magnetic resonance imaging. Predictive model for potential metastasic Prostate Cancer. Fundació La Marató de TV3, ref. 201922. 19/07/2020-19/07/2022. IP: Drs. E. Llop (University of Girona) and J. Comet (IdIbGi).
- Influencia de la glicosilación alterada en cáncer de páncreas. Estrategias glicoproteómicas para la búsqueda de nuevos marcadores tumorales. MINECO BIO2015-66356-R. - 01/2016- 12/2018. IP: Rosa Peracaula/Rafael de LLorens
Grupo de investigación consolidado: Bioquímica y Clínica del Cáncer. Generalitat de Catalunya. V Pla de Recerca de Catalunya. Ref. SGR 2017-673. 2017- 2021. IP: Rafael de Llorens
Grupo de investigación consolidado: Bioquímica y Clínica del Cáncer. Generalitat de Catalunya. IV Pla de Recerca de Catalunya. Ref. SGR 2014-229. 2014 - 2017. IP: Rafael de Llorens
Glicosilación alterada en cáncer: Glicoproteínas y glicosiltransferasas en suero y tejidos como marcadores tumorales. MICINN (Gobierno de España)-Ref. BIO2010-16922. 2011-2013. IP: Rosa Peracaula Miró
Grupo de investigación consolidado. Generalitat de Catalunya. III Pla de Recerca de Catalunya. Ref. 2009SGR-717. 2009 - 2012. IP: Rafael de Llorens
Mecanismo de resistencia tumoral a través de la vía EGFR. Universidad de Girona. 2008. IP: Rafael de Llorens
Altered glycosylation in tumours: Potential use of serum glycoproteins as tumour markers. MCIIN (Gobierno de España)-Ref. BIO2007-61323. 2007-2010. IP: Rosa Peracaula Miró
Thematic cooperative research nets in medicine. Thematic research net in cancer. Instituto de Salud Carlos III. 2007-2010. IP: Ramon Colomer
Role of Glycosyltransferases in the invasive and metastatic potential of pancreatic adenocarcinoma. Ref: (050932, 2005). Fundació La Marató. 2006-2009. IP: Rosa Peracaula Miró
Grupo de investigación consolidado. Generalitat de Catalunya. II Pla de Recerca de Catalunya. Ref. SGR 2005-00065. 2006-2009. IP: Rafael de Llorens
Aberrant glycosylation of serum proteins as tumour markers. MCYT (Gobierno de España)-Ref. BIO2004-00438. 2004-2007. IP: Rosa Peracaula Miró
Publications (last 10 years):
- Miró L, López J, Guerrero PE, Martínez-Bosch N, Manero-Rupérez N, Moreno M, Ortiz MR, Llop E, Navarro P, Peracaula R. Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice. Cancers (Basel) 2022; 14(24):6133. doi: 10.3390/cancers14246133.
- Duran A, Guerrero PE, Ortiz MR, Pérez Del Campo D, Castro E, Garcia-Velasco A, Fort E, de Llorens R, Saldova R, Llop E, Peracaula R. 2022. Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera. Biomedicines 2022; 10(8):1942. doi: 10.3390/biomedicines10081942.
- Esther Llop and Rosa Peracaula. "Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer" (Chapter 15). Methods in Molecular Biology 2022, Vol. 2370: Glycosylation, Methods and Protocols, pp. 301-313. Gavin Davey (Eds). Springer. ISBN: 978-1-0716-1684-0.
- Greville G, Llop E, Howard J, Madden SF, Perry AS, Peracaula R, Rudd PM, McCann A, Saldova R. 5-AZA-dC induces epigenetic changes associated with modified glycosylation of secreted glycoproteins and increased EMT and migration in chemo-sensitive cancer cells. Clin Epigenetics. 2021, 13(1):34. doi: 10.1186/s13148-021-01015-7
- Gratacós-Mulleras A, Duran A, Asadi Shehni A, Ferrer-Batallé M, Ramírez M, Comet J, de Llorens R, Saldova R, Llop E, Peracaula R. Characterisation of the main PSA glycoforms in aggressive prostate cancer. Scientific Reports 2020, 10(1):18974. doi: 10.1038/s41598-020-75526-3.
-Greville G, Llop E, Huang C, Creagh-Flynn J, Pfister S, O'Flaherty R, Madden SF, Peracaula R, Rudd PM, McCann A, Saldova R. Hypoxia Alters Epigenetic and N-Glycosylation Profiles of Ovarian and Breast Cancer Cell Lines in-vitro. Front Oncol. 2020, 10:1218. doi: 10.3389/fonc.2020.01218. eCollection 2020.
- Guerrero PE, Miró L, Wong BS, Massaguer A, Martínez-Bosch N, Llorens R, Navarro P, Konstantopoulos K, Llop E, Peracaula R. Knockdown of α2,3-Sialyltransferases Impairs Pancreatic Cancer Cell Migration, Invasion and E-selectin-Dependent Adhesion. Int J Mol Sci. 2020 Aug 28;21(17):6239. doi: 10.3390/ijms21176239.
- Guerrero PE, Duran A, Ortiz MR, Castro E, Garcia-Velasco A, Llop E, Peracaula R. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLex) in pancreatic adenocarcinoma. J Proteomics. 2020;231:104004. doi: 10.1016/j.jprot.2020.104004.
- Mancera-Arteu M, Giménez E, Balmaña M, Barrabés S, Albiol-Quer M, Fort E, Peracaula R, Sanz-Nebot V. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma. J Proteomics. 2019; 195:76-87. doi: 10.1016/j.jprot.2019.01.006
- Balmaña M, Duran A, Gomes C, Llop E, López-Martos R, Ortiz MR, Barrabés S, Reis CA, Peracaula R. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues. Int J Biol Macromol. 2018;112:33-45. doi: 10.1016/j.ijbiomac.2018.01.148.
- Llop E, E Guerrero P, Duran A, Barrabés S, Massaguer A, José Ferri M, Albiol-Quer M, de Llorens R, Peracaula R. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. World J Gastroenterol. 2018;24:2537-2554.
- Mancera-Arteu M, Giménez E, Barbosa J, Peracaula R, Sanz-Nebot V. Zwitterionic-hydrophilic interaction capillary liquid chromatography coupled to tandem mass spectrometry for the characterization of human alpha-acid-glycoprotein N-glycan isomers. Anal Chim Acta. 2017;991:76-88. doi: 10.1016/j.aca.2017.07.068
- Ferrer-Batallé M, Llop E, Ramírez M, Aleixandre RN, Saez M, Comet J, de Llorens R, Peracaula R. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. Int J Mol Sci. 2017;18(4). pii: E845. doi: 10.3390/ijms18040845.
-Barrabés S, Llop E, Ferrer-Batallé M, Ramírez M, Aleixandre RN, Perry AS, de Llorens R, Peracaula R. Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer. Clin Chim Acta 2017, 470:97-102. doi: 10.1016/j.cca.2017.05.009
- Barrabés S, Farina-Gomez N, Llop E, Puerta A, Diez-Masa JC, Perry A, de Llorens R, de Frutos M, Peracaula R. Comparative analysis of prostate-specific antigen by two-dimensional gel electrophoresis and capillary electrophoresis. Electrophoresis. 2016 Oct 2. doi: 10.1002/elps.201600432
- Llop E, Ferrer-Batallé M, Barrabés S, Guerrero PE, Ramírez M, Saldova R, Rudd PM, Aleixandre RN, Comet J, de Llorens R, Peracaula R. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics 2016;6(8):1190-204.
- Ferri MJ, Saez M, Figueras J, Fort E, Sabat M, López-Ben S, de Llorens R, Aleixandre RN, Peracaula R. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology. PLoS One. 2016;11(1):e0147214.
- Balmaña M, Giménez E, Puerta A, Llop E, Figueras J, Fort E, Sanz-Nebot V, de Bolós C, Rizzi A, Barrabés S, de Frutos M, Peracaula R. Increased α1-3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer. J Proteomics. 2016;132:144-54.
- Bassagañas S, Allende H, Cobler L, Ortiz MR, Llop E, de Bolós C, Peracaula R. Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines. Cytokine. 2015;75(1):197-206. doi: 10.1016/j.cyto.2015.04.006.
- Giménez E, Balmaña M, Figueras J, Fort E, de Bolós C, Sanz-Nebot V, Peracaula R, Rizzi A. Quantitative analysis of N-glycans from human alfa-acid-glycoprotein using stable isotope labeling and zwitterionic hydrophilic interaction capillary liquid chromatography electrospray mass spectrometry as tool for pancreatic disease diagnosis. Anal Chim Acta. 2015;866:59-68. doi: 10.1016/j.aca.2015.02.008.
- Balmaña M, Sarrats A, Llop E, Barrabés S, Saldova R, Ferri MJ, Figueras J, Fort E, de Llorens R, Rudd PM, Peracaula R. Identification of potential pancreatic cancer serum markers: Increased sialyl-Lewis X on ceruloplasmin. Clin Chim Acta. 2015;442:56-62. doi: 10.1016/j.cca.2015.01.007.
- Bassagañas S, Carvalho S, Dias AM, Pérez-Garay M, Ortiz MR, Figueras J, Reis CA, Pinho SS, Peracaula R. Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of α2β1 integrin and E-cadherin function. PLoS One. 2014;9(5):e98595. doi:10.1371/journal.pone.0098595.
- Saldova R, Piccard H, Pérez-Garay M, Harvey DJ, Struwe WB, Galligan MC, Berghmans N, Madden SF, Peracaula R, Opdenakker G, Rudd PM. Increase in sialylation and branching in the mouse serum N-glycome correlates with inflammation and ovarian tumour progression. PLoS One. 2013 ;8(8):e71159. doi: 10.1371/journal.pone.0071159.
- Bassagañas S, Pérez-Garay M, Peracaula R. Cell surface sialic acid modulates extracellular matrix adhesion and migration in pancreatic adenocarcinoma cells. Pancreas. 2014;43(1):109-17. doi: 10.1097/MPA.0b013e31829d9090.
- Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolós C, Figueras J, de Llorens R, Vidal-Vanaclocha F, Peracaula R. α2,3-Sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int J Biochem Cell Biol. 2013;45(8):1748-57. doi: 10.1016/j.biocel.2013.05.015.
- Saldova R, Dempsey E, Pérez-Garay M, Mariño K, Watson JA, Blanco-Fernández A, Struwe WB, Harvey DJ, Madden SF, Peracaula R, McCann A, Rudd PM. 5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics. 2011 Nov 1;6(11).
- Padró M, Mejías-Luque R, Cobler L, Garrido M, Pérez-Garay M, Puig S, Peracaula R, de Bolós C. Regulation of glycosyltransferases and Lewis antigens expression by IL-1ß and IL-6 in human gastric cancer cells. Glycoconj J. 2011 ;28(2):99-110
- Sarrats A, Saldova R, Pla E, Fort E, Harvey DJ, Struwe WB, de Llorens R, Rudd PM, Peracaula R. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl. 2010 ;4(4):432-48. doi: 10.1002/prca.200900150.
- Peracaula R, Sarrats A, Rudd PM Liver proteins as sensor of human malignancies and inflammation. Proteomics Clin Appl. 2010 ;4(4):426-31. doi: 10.1002/prca.200900170.
- Pérez-Garay M, Arteta B, Pagès L, de Llorens R, de Bolòs C, Vidal-Vanaclocha F, Peracaula R. alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS One. 2010 ;5(9). pii: e12524.
- Sarrats A, Saldova R, Comet J, O'Donoghue N, de Llorens R, Rudd PM, Peracaula R. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. OMICS. 2010;14(4):465-74.
- Barrabés S, Sarrats A, Fort E, De Llorens R, Rudd PM, Peracaula R. Effect of sialic acid content on glycoprotein pI analyzed by two-dimensional electrophoresis. Electrophoresis. 2010;31(17):2903-12.
- Sarrats A, Comet J, Tabarés G, Ramírez M, Aleixandre RN, de Llorens R, Peracaula R. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. Prostate. 2010 ;70(1):1-9.
- Peracaula R, Barrabés S, Sarrats A, Rudd PM, de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers. 2008;25(4-5):207-18. Review.
- Tabarés G, Jung K, Reiche J, Stephan C, Lein M, Peracaula R, de Llorens R, Hoesel W. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples. Clin Biochem. 2007 ;40(5-6):343-50.
- Barrabés S, Pagès-Pons L, Radcliffe CM, Tabarés G, Fort E, Royle L, Harvey DJ, Moenner M, Dwek RA, Rudd PM, De Llorens R, Peracaula R. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology. 2007 ;17(4):388-400.
- Tabarés G, Radcliffe CM, Barrabés S, Ramírez M, Aleixandre RN, Hoesel W, Dwek RA, Rudd PM, Peracaula R, de Llorens R. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology. 2006 ;16(2):132-45.
- Peracaula R, Tabarés G, López-Ferrer A, Brossmer R, de Bolós C, de Llorens R. Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells. Glycoconj J. 2005 ;22(3):135-44.
- Peracaula R, Royle L, Tabares G, Mallorqui-Fernández G, Barrabés S, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states. Glycobiology. 2003;13(4):227-44.
- Peracaula R, Tabarés G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology. 2003 ;13(6):457-70.
- Pous J, Mallorquí-Fernández G, Peracaula R, Terzyan SS, Futami J, Tada H, Yamada H, Seno M, de Llorens R, Gomis-Rüth FX, Coll M. Three-dimensional structure of human RNase 1 delta N7 at 1.9 A resolution. Acta Crystallogr D Biol Crystallogr. 2001 ;57(Pt 4):498-505.
- Peracaula R, Cleary KR, Lorenzo J, de Llorens R, Frazier ML. Human pancreatic ribonuclease 1: expression and distribution in pancreatic adenocarcinoma. Cancer. 2000;89(6):1252-8.
- Mallorquí-Fernández G, Pous J, Peracaula R, Aymamí J, Maeda T, Tada H, Yamada H, Seno M, de Llorens R, Gomis-Rüth FX, Coll M. Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 A resolution. J Mol Biol. 2000;300(5):1297-307.
- Fernández-Salas E, Peracaula R, Frazier ML, de Llorens R. Ribonucleases expressed by human pancreatic adenocarcinoma cell lines. Eur J Biochem. 2000 ;267(5):1484-94.
- Terzyan SS, Peracaula R, de Llorens R, Tsushima Y, Yamada H, Seno M, Gomis-Rüth FX, Coll M. The three-dimensional structure of human RNase 4, unliganded and complexed with d(Up), reveals the basis for its uridine selectivity. J Mol Biol. 1999 ;285(1):205-14.
Patents:
- Óscar Pozo, Àlex Gomez, Gabriel Gil, Manuel Pera, Laura Visa, Edurne Arriola, Rosa Peracaula, Esther Llop, Ernesto Castro, Adelaida Garcia, Esther Fort, Dúnia Pérez. “Method for diagnosing cancer”. EP22382244.6. 14.03.2022. Fundació Institut Mar d’Investigacions Mèdiques (IMIM), Univ. de Girona/Fundació Institut d’Investigació Biomèdica de Girona Dr.Josep Trueta, Institut Català d’Oncologia..
-R. Peracaula, R de Llorens, E. Llop, M. Ferrer-Batallé, S. Barrabés, J. Comet, RN. Aleixandre, M. Ramírez, PM Rudd, R. Saldova. “Método in vitro para el diagnóstico del cáncer de próstata” PCT/ES2016/070781 06.11.2015. Univ. de Girona/Fundació Institut d’Investigació Biomèdica de Girona Dr.Josep Trueta.
- R. Peracaula, MJ. Ferri, M. Saez, J, Figueras, RN, Aleixandre, R de Llorens. “Combinatoria de los marcadores clínicos CA19.9, CEA, IGF-1 y albúmina que mejoran el diagnóstico del cáncer de páncreas frente la pancreatitis crònica”. PCT/ES2015/070529. 08.07.2014. Univ. de Girona/Hospital Josep Trueta.
- Rudd, P.M Dwek R.A.; Treacy, M. ; O'Driscoll, K., De Llorens R., Peracaula R. “Glycosylation Markers for Cancer and Chronic Inflammation”. PCT/GB2008/050607. USA. 21.07.2008. Universidad de Oxford/NIBRT-University College Dublin/Universidad de Girona.
-Dwek R.A.; De Llorens R., Peracaula R., Radcliffe C.M.; Royle L.;Rudd, P.M.; Zitzmann N. Glycosylation markers for cancer diagnosing and monitoring PCT/IB2005/002531. USA. 24.06.2005. Universidad de Oxford/Universidad de Girona.